James French Hill
Suspicious Timing Detected
4 flagsRep. James French Hill sold $100,001 - $250,000 in $PFE on 2025-12-31 — 68 days before HR7879, the "SUPER BUGS Act of 2026," was introduced, which directs a strategy for international collaboration on pandemic products.
Rep. James French Hill sold $100,001 - $250,000 in $PFE on 2025-12-31 — 71 days before HR7902 was introduced, a bill that would withdraw FDA approval for mifepristone.
These flags identify timing coincidences between stock trades and legislative activity. They do not imply wrongdoing. Click any bill number or ticker to see the full analysis.
Share This Filing
All Transactions
Connected Legislative Activity
10 signalsThese bills and contracts share tickers or sectors with this filing's trades.
Protecting Americans from Unsafe Drugs Act of 2026
The 'Protecting Americans from Unsafe Drugs Act of 2026' expands drug recall authority to all drugs, increasing compliance costs and liability for pharmaceutical manufacturers. This directly elevates operational expenses and risks for major pharmaceutical companies. The bill creates a significant headwind for the pharmaceutical sector.
To require the Secretary of State, in consultation with the Secretary of Health and Human Services and other relevant departments and agencies, as appropriate, to formulate a strategy for the Federal Government to secure support from foreign countries, multilateral organizations, and other appropriate entities to facilitate the development and commercialization of qualified pandemic or epidemic products, and for other purposes.
HR7879, the "SUPER BUGS Act of 2026," introduced on March 9, 2026, directs the Secretary of State to formulate a strategy for international collaboration on pandemic product development. This bill is in its early stages, referred to the House Committee on Foreign Affairs, and does not authorize specific funding, thus having no immediate direct financial impact on companies. However, it signals potential future policy that could benefit pharmaceutical and biotechnology companies by expanding global market access for qualified pandemic or epidemic products.
A bill to direct the Director of the Bureau of Justice Statistics to establish a database with respect to corporate offenses, and for other purposes.
The Corporate Crime Database Act of 2026 (S.4104) introduces a federal database for corporate offenses, increasing compliance costs and legal risks for all publicly traded companies. This legislation, currently in the early stages of referral to committee, mandates public dissemination of corporate enforcement actions, potentially leading to heightened regulatory scrutiny and reputational damage across all sectors. Companies with complex operations and existing regulatory issues face the most significant negative impact.
To amend title XVIII of the Social Security Act to require PDP sponsors of a prescription drug plan under part D of the Medicare program that use a formulary to include certain generic drugs and biosimilar biological products on such formulary, and for other purposes.
HR8143 mandates Medicare Part D plans to include generic and biosimilar drugs on formularies, directly reducing brand-name drug sales and increasing generic/biosimilar market share. This legislation will decrease pharmaceutical company revenues from patented drugs and lower pharmacy benefit manager (PBM) margins on brand-name drugs.
Maternal Vaccination Act
The Maternal Vaccination Act, HR8024, allocates $17,000,000 annually from 2027-2031 for maternal vaccination awareness, creating sustained demand for maternal vaccines. This directly benefits pharmaceutical companies producing these vaccines. The bill amends the Public Health Service Act to increase funding for awareness campaigns targeting pregnant and postpartum individuals.
To provide that the approved application under the Federal Food, Drug, and Cosmetic Act for the drug mifepristone for the purpose of the termination of intrauterine pregnancy is deemed to have been withdrawn, to establish a Federal tort for harm to women caused by chemical abortion drugs, and for other purposes.
This bill directly withdraws FDA approval for mifepristone, eliminating its market and establishing a federal tort for chemical abortion drug harm. This action shifts demand to surgical abortion services and emergency care, creating significant financial and operational challenges for healthcare providers and pharmaceutical companies.
End Veterans Overdose Act of 2026
The End Veterans Overdose Act of 2026 mandates the VA to provide opioid overdose rescue medications free of charge, creating a guaranteed revenue stream for pharmaceutical manufacturers and increasing dispensing volume for pharmacies. This directly expands the market for these medications within the VA system.
To require the Secretary of Health and Human Services to establish a demonstration program to test mandatory coverage of treatment for wound care for epidermolysis bullosa under the Medicaid program.
HR7877, the "Shane DiGiovanna Act," introduced on March 9, 2026, mandates a nationwide Medicaid demonstration program for epidermolysis bullosa wound care, creating a new, guaranteed revenue stream for pharmaceutical and medical supply companies. This bill directly increases demand for specific over-the-counter medications and wound care supplies by expanding covered services under Medicaid.
Maternal Vaccinations Act
The Maternal Vaccinations Act increases funding for maternal vaccination awareness and equity campaigns, directly boosting demand for maternal vaccines. This legislation creates a sustained revenue stream for pharmaceutical companies producing these vaccines. The bill's referral to committee indicates initial legislative movement.
To amend title XVIII of the Social Security Act to ensure equitable payment for, and preserve Medicare beneficiary access to, cancer treatments under the Medicare hospital outpatient prospective payment system.
HR8032 stabilizes Medicare reimbursement for cancer treatments in outpatient settings, directly benefiting pharmaceutical and biotech companies focused on oncology. This legislation secures revenue streams for cancer drug manufacturers by creating a predictable financial environment for cancer care providers and drug suppliers. Companies with significant oncology portfolios see immediate upside.
Data sourced from the U.S. House of Representatives Office of the Clerk Financial Disclosure system. Stock prices from Financial Modeling Prep. Suspicious timing flags identify coincidences between stock trades and legislative activity and do not imply any wrongdoing or illegal activity. This is not financial advice.